Diagnosis and Management of Chronic Lymphocytic Leukemia with TP53 Loss of Function in the Novel Agent Era.

Continuous covalent BTK inhibitor therapy achieves a median progression-free survival of approximately 7 years in TP53-loss-of-function chronic lymphocytic leukemia, establishing it as the standard of care.

• Why it matters: TP53 loss-of-function is the most critical prognostic factor in CLL, and effective management strategies are essential to improve patient outcomes, especially given historically poor responses to chemoimmunotherapy.
• What they did: The study reviews current treatment approaches, emphasizing the effectiveness of continuous cBTKi therapy in the novel agent era, and compares it with fixed-duration regimens involving venetoclax combinations, analyzing their response kinetics and PFS.
• The result: Findings support continuous cBTKi as the preferred management for TP53-LoF CLL, while highlighting the need for careful consideration of fixed-duration regimens' risks and benefits, especially regarding retreatment outcomes and MRD status.